Report Store mobile icon
Global Beta-lactam and Beta-lactamase Inhibitors Market Growth 2024-2030
Global Beta-lactam and Beta-lactamase Inhibitors Market Growth 2024-2030

2024

Global Beta-lactam and Beta-lactamase Inhibitors Market Growth 2024-2030

Beta-lactam and Beta-lactamase Inhibitors market rises from US$26.74 billion in 2023 to US$30.74 billion by 2030, with a 2.0% CAGR, driven by increasing demand in the downstream ma

Buy Now Get Free sample

New Report Guarantee

If you purchase this report now and we update it in new 100 days, get it free!

The global beta-lactam and beta-lactamase inhibitors market stands on the frontlines of a fierce battle against bacterial foes. For decades, beta-lactam antibiotics have been a cornerstone of antibiotic therapy, effectively combating a wide range of bacterial infections. However, the misuse and overuse of these antibiotics have created a nightmarish scenario: the emergence and spread of antibiotic-resistant bacteria. These resilient pathogens have developed mechanisms to thwart the effects of beta-lactam antibiotics, rendering them ineffective. This phenomenon, known as antibiotic resistance, poses a significant threat to global health, making it increasingly difficult to treat common bacterial infections. Here's where beta-lactamase inhibitors enter the scene as powerful allies. Bacteria can produce enzymes called beta-lactamases that act like molecular scissors, chopping up beta-lactam antibiotics and disarming them. Beta-lactamase inhibitors are a class of drugs specifically designed to disarm these bacterial weapons. They bind to beta-lactamase enzymes, rendering them inactive and protecting beta-lactam antibiotics from their destructive effects. This ingenious combination therapy allows beta-lactam antibiotics to function effectively against bacteria that would otherwise be resistant, providing clinicians with a crucial tool to combat infections. According to our publisher’s study, the global Beta-lactam and Beta-lactamase Inhibitors market size was valued at US$ 26740 million in 2023. With growing demand in downstream market, the Beta-lactam and Beta-lactamase Inhibitors is forecast to a readjusted size of US$ 30740 million by 2030 with a CAGR of 2.0% during review period.

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

The research report highlights the growth potential of the global Beta-lactam and Beta-lactamase Inhibitors market. Beta-lactam and Beta-lactamase Inhibitors are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Beta-lactam and Beta-lactamase Inhibitors. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Beta-lactam and Beta-lactamase Inhibitors market. ?-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related ?-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to ?-lactams is primarily because of bacterially produced ?-lactamase enzymes that hydrolyze the ?-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum ?-lactamase inhibitors that work against many problematic ?-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options. Global key players of beta-lactam and beta-lactamase Inhibitors include Pfizer, USantibiotics, TEVA, Novartis (Sandoz), Antibiotice. Global top five manufacturers hold a share over 10%. Asia-Pacific is the largest market of beta-lactam and beta-lactamase Inhibitors, holds a share over 30%, followed by Europe, and North America, with a share of 30% and 20% respectively. In terms of product, cephalosporins is the largest segment, with a share over 38%. And in terms of application, the largest application is in Intravenous with a share about 50%.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Key Features: The report on Beta-lactam and Beta-lactamase Inhibitors market reflects various aspects and provide valuable insights into the industry. Market Size and Growth: The research report provide an overview of the current size and growth of the Beta-lactam and Beta-lactamase Inhibitors market. It may include historical data, market segmentation by Type (e.g., Penicillins, Cephalosporins), and regional breakdowns.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Beta-lactam and Beta-lactamase Inhibitors market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs. Market Dynamics in Beta-Lactams and Beta-Lactamase Inhibitors Market Drivers: • Rising Antibiotic Resistance: Increased prevalence of multidrug-resistant bacteria fuels demand for effective therapies like beta-lactam/beta-lactamase inhibitor combinations. • Focus on Hospital Infections: Growing concern about hospital-acquired infections drives the need for broad-spectrum antibiotics like these combinations. Market Trends: • Emerging Market Focus: Developing economies with growing populations and healthcare spending are expected to be significant contributors to market growth. • New Drug Development: Ongoing research efforts target novel beta-lactam antibiotics and beta-lactamase inhibitors with improved efficacy and broader spectrums. Market Challenges: • Antibiotic Resistance Evolution: The continuous emergence of new resistance mechanisms in bacteria threatens the long-term effectiveness of these drugs. • Strict Regulations: Stringent regulations governing drug development can hinder the introduction of innovative beta-lactam and beta-lactamase inhibitor therapies. Competitive Landscape: The research report provides analysis of the competitive landscape within the Beta-lactam and Beta-lactamase Inhibitors market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market. Technological Developments: The research report can delve into the latest technological developments in the Beta-lactam and Beta-lactamase Inhibitors industry. This include advancements in Beta-lactam and Beta-lactamase Inhibitors technology, Beta-lactam and Beta-lactamase Inhibitors new entrants, Beta-lactam and Beta-lactamase Inhibitors new investment, and other innovations that are shaping the future of Beta-lactam and Beta-lactamase Inhibitors. • New Beta-lactam Designs: Research focuses on developing novel beta-lactam antibiotics with broader spectrums to combat a wider range of bacteria. • Improved Inhibitor Efficacy: Scientists are engineering more potent beta-lactamase inhibitors to effectively disarm these resistance enzymes. • Combination Strategies: Exploring innovative drug combinations, including beta-lactam/inhibitor therapies alongside other antibiotics, to enhance effectiveness against resistant strains. Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Beta-lactam and Beta-lactamase Inhibitors market. It includes factors influencing customer ' purchasing decisions, preferences for Beta-lactam and Beta-lactamase Inhibitors product. Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Beta-lactam and Beta-lactamase Inhibitors market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Beta-lactam and Beta-lactamase Inhibitors market. The report also evaluates the effectiveness of these policies in driving market growth. Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Beta-lactam and Beta-lactamase Inhibitors market. Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Beta-lactam and Beta-lactamase Inhibitors industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments. • Combating Resistance: Focus on antibiotic stewardship and novel drug development to stay ahead of evolving resistant bacteria. • Emerging Market Growth: Rising healthcare spending and increasing infections in developing economies will fuel market expansion. • Innovation Push: Research into new beta-lactam antibiotics with broader spectrums and more potent inhibitors is crucial for long-term success. Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Beta-lactam and Beta-lactamase Inhibitors market. • Antibiotic Stewardship: Promote responsible use of these antibiotics to curb resistance and extend their effectiveness. • Innovation Pipeline: Invest in research for next-generation beta-lactam antibiotics and inhibitors with broader spectrums and improved efficacy. • Combination Strategies: Explore effective combinations of beta-lactam/inhibitor therapies with other antibiotics to combat resistant bacteria. Market Segmentation: Beta-lactam and Beta-lactamase Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. Segmentation by type Penicillins Cephalosporins Carbapenems Monobactams Combinations Segmentation by application Oral Intravenous This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Pfizer Novartis (Sandoz) TEVA Merck & Co. AbbVie (Allergan) Sumitomo Dainippon Hikma Aurobindo Pharma Wockhardt Lupin Limited Fresenius Kabi B. Braun USantibiotics Qilu Pharmaceutical ACS Dobfar Nichi-Iko (Sagent) Antibiotice

Table of Contents

  • 1 Scope of the Report
  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats
  • 2 Executive Summary
  • 2.1 World Market Overview
  • 2.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Annual Sales 2019-2030
  • 2.1.2 World Current & Future Analysis for Beta-lactam and Beta-lactamase Inhibitors by Geographic Region, 2019, 2023 & 2030
  • 2.1.3 World Current & Future Analysis for Beta-lactam and Beta-lactamase Inhibitors by Country/Region, 2019, 2023 & 2030
  • 2.2 Beta-lactam and Beta-lactamase Inhibitors Segment by Type
  • 2.2.1 Penicillins
  • 2.2.2 Cephalosporins
  • 2.2.3 Carbapenems
  • 2.2.4 Monobactams
  • 2.2.5 Combinations
  • 2.3 Beta-lactam and Beta-lactamase Inhibitors Sales by Type
  • 2.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2019-2024)
  • 2.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue and Market Share by Type (2019-2024)
  • 2.3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sale Price by Type (2019-2024)
  • 2.4 Beta-lactam and Beta-lactamase Inhibitors Segment by Application
  • 2.4.1 Oral
  • 2.4.2 Intravenous
  • 2.5 Beta-lactam and Beta-lactamase Inhibitors Sales by Application
  • 2.5.1 Global Beta-lactam and Beta-lactamase Inhibitors Sale Market Share by Application (2019-2024)
  • 2.5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue and Market Share by Application (2019-2024)
  • 2.5.3 Global Beta-lactam and Beta-lactamase Inhibitors Sale Price by Application (2019-2024)
  • 3 Global Beta-lactam and Beta-lactamase Inhibitors by Company
  • 3.1 Global Beta-lactam and Beta-lactamase Inhibitors Breakdown Data by Company
  • 3.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Annual Sales by Company (2019-2024)
  • 3.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Company (2019-2024)
  • 3.2 Global Beta-lactam and Beta-lactamase Inhibitors Annual Revenue by Company (2019-2024)
  • 3.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Company (2019-2024)
  • 3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Company (2019-2024)
  • 3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sale Price by Company
  • 3.4 Key Manufacturers Beta-lactam and Beta-lactamase Inhibitors Producing Area Distribution, Sales Area, Product Type
  • 3.4.1 Key Manufacturers Beta-lactam and Beta-lactamase Inhibitors Product Location Distribution
  • 3.4.2 Players Beta-lactam and Beta-lactamase Inhibitors Products Offered
  • 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Beta-lactam and Beta-lactamase Inhibitors by Geographic Region
  • 4.1 World Historic Beta-lactam and Beta-lactamase Inhibitors Market Size by Geographic Region (2019-2024)
  • 4.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Annual Sales by Geographic Region (2019-2024)
  • 4.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Annual Revenue by Geographic Region (2019-2024)
  • 4.2 World Historic Beta-lactam and Beta-lactamase Inhibitors Market Size by Country/Region (2019-2024)
  • 4.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Annual Sales by Country/Region (2019-2024)
  • 4.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Annual Revenue by Country/Region (2019-2024)
  • 4.3 Americas Beta-lactam and Beta-lactamase Inhibitors Sales Growth
  • 4.4 APAC Beta-lactam and Beta-lactamase Inhibitors Sales Growth
  • 4.5 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Growth
  • 4.6 Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales Growth
  • 5 Americas
  • 5.1 Americas Beta-lactam and Beta-lactamase Inhibitors Sales by Country
  • 5.1.1 Americas Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2019-2024)
  • 5.1.2 Americas Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2019-2024)
  • 5.2 Americas Beta-lactam and Beta-lactamase Inhibitors Sales by Type
  • 5.3 Americas Beta-lactam and Beta-lactamase Inhibitors Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil
  • 6 APAC
  • 6.1 APAC Beta-lactam and Beta-lactamase Inhibitors Sales by Region
  • 6.1.1 APAC Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2019-2024)
  • 6.1.2 APAC Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2019-2024)
  • 6.2 APAC Beta-lactam and Beta-lactamase Inhibitors Sales by Type
  • 6.3 APAC Beta-lactam and Beta-lactamase Inhibitors Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan
  • 7 Europe
  • 7.1 Europe Beta-lactam and Beta-lactamase Inhibitors by Country
  • 7.1.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2019-2024)
  • 7.1.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2019-2024)
  • 7.2 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Type
  • 7.3 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia
  • 8 Middle East & Africa
  • 8.1 Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors by Country
  • 8.1.1 Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2019-2024)
  • 8.1.2 Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2019-2024)
  • 8.2 Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Type
  • 8.3 Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends
  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis
  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Beta-lactam and Beta-lactamase Inhibitors
  • 10.3 Manufacturing Process Analysis of Beta-lactam and Beta-lactamase Inhibitors
  • 10.4 Industry Chain Structure of Beta-lactam and Beta-lactamase Inhibitors
  • 11 Marketing, Distributors and Customer
  • 11.1 Sales Channel
  • 11.1.1 Direct Channels
  • 11.1.2 Indirect Channels
  • 11.2 Beta-lactam and Beta-lactamase Inhibitors Distributors
  • 11.3 Beta-lactam and Beta-lactamase Inhibitors Customer
  • 12 World Forecast Review for Beta-lactam and Beta-lactamase Inhibitors by Geographic Region
  • 12.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast by Region
  • 12.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Forecast by Region (2025-2030)
  • 12.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Annual Revenue Forecast by Region (2025-2030)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Beta-lactam and Beta-lactamase Inhibitors Forecast by Type
  • 12.7 Global Beta-lactam and Beta-lactamase Inhibitors Forecast by Application
  • 13 Key Players Analysis
  • 13.1 Pfizer
  • 13.1.1 Pfizer Company Information
  • 13.1.2 Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.1.4 Pfizer Main Business Overview
  • 13.1.5 Pfizer Latest Developments
  • 13.2 Novartis (Sandoz)
  • 13.2.1 Novartis (Sandoz) Company Information
  • 13.2.2 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.2.4 Novartis (Sandoz) Main Business Overview
  • 13.2.5 Novartis (Sandoz) Latest Developments
  • 13.3 TEVA
  • 13.3.1 TEVA Company Information
  • 13.3.2 TEVA Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.3.4 TEVA Main Business Overview
  • 13.3.5 TEVA Latest Developments
  • 13.4 Merck & Co.
  • 13.4.1 Merck & Co. Company Information
  • 13.4.2 Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.4.3 Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.4.4 Merck & Co. Main Business Overview
  • 13.4.5 Merck & Co. Latest Developments
  • 13.5 AbbVie (Allergan)
  • 13.5.1 AbbVie (Allergan) Company Information
  • 13.5.2 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.5.4 AbbVie (Allergan) Main Business Overview
  • 13.5.5 AbbVie (Allergan) Latest Developments
  • 13.6 Sumitomo Dainippon
  • 13.6.1 Sumitomo Dainippon Company Information
  • 13.6.2 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.6.4 Sumitomo Dainippon Main Business Overview
  • 13.6.5 Sumitomo Dainippon Latest Developments
  • 13.7 Hikma
  • 13.7.1 Hikma Company Information
  • 13.7.2 Hikma Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.7.4 Hikma Main Business Overview
  • 13.7.5 Hikma Latest Developments
  • 13.8 Aurobindo Pharma
  • 13.8.1 Aurobindo Pharma Company Information
  • 13.8.2 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.8.4 Aurobindo Pharma Main Business Overview
  • 13.8.5 Aurobindo Pharma Latest Developments
  • 13.9 Wockhardt
  • 13.9.1 Wockhardt Company Information
  • 13.9.2 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.9.4 Wockhardt Main Business Overview
  • 13.9.5 Wockhardt Latest Developments
  • 13.10 Lupin Limited
  • 13.10.1 Lupin Limited Company Information
  • 13.10.2 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.10.4 Lupin Limited Main Business Overview
  • 13.10.5 Lupin Limited Latest Developments
  • 13.11 Fresenius Kabi
  • 13.11.1 Fresenius Kabi Company Information
  • 13.11.2 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.11.4 Fresenius Kabi Main Business Overview
  • 13.11.5 Fresenius Kabi Latest Developments
  • 13.12 B. Braun
  • 13.12.1 B. Braun Company Information
  • 13.12.2 B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.12.4 B. Braun Main Business Overview
  • 13.12.5 B. Braun Latest Developments
  • 13.13 USantibiotics
  • 13.13.1 USantibiotics Company Information
  • 13.13.2 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.13.4 USantibiotics Main Business Overview
  • 13.13.5 USantibiotics Latest Developments
  • 13.14 Qilu Pharmaceutical
  • 13.14.1 Qilu Pharmaceutical Company Information
  • 13.14.2 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.14.4 Qilu Pharmaceutical Main Business Overview
  • 13.14.5 Qilu Pharmaceutical Latest Developments
  • 13.15 ACS Dobfar
  • 13.15.1 ACS Dobfar Company Information
  • 13.15.2 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.15.4 ACS Dobfar Main Business Overview
  • 13.15.5 ACS Dobfar Latest Developments
  • 13.16 Nichi-Iko (Sagent)
  • 13.16.1 Nichi-Iko (Sagent) Company Information
  • 13.16.2 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.16.4 Nichi-Iko (Sagent) Main Business Overview
  • 13.16.5 Nichi-Iko (Sagent) Latest Developments
  • 13.17 Antibiotice
  • 13.17.1 Antibiotice Company Information
  • 13.17.2 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
  • 13.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.17.4 Antibiotice Main Business Overview
  • 13.17.5 Antibiotice Latest Developments
  • 14 Research Findings and Conclusion

List of Tables
Table 1. Beta-lactam and Beta-lactamase Inhibitors Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Beta-lactam and Beta-lactamase Inhibitors Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Penicillins
Table 4. Major Players of Cephalosporins
Table 5. Major Players of Carbapenems
Table 6. Major Players of Monobactams
Table 7. Major Players of Combinations
Table 8. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2019-2024) & (M Units)
Table 9. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2019-2024)
Table 10. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2019-2024) & ($ million)
Table 11. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2019-2024)
Table 12. Global Beta-lactam and Beta-lactamase Inhibitors Sale Price by Type (2019-2024) & (US$/Unit)
Table 13. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2019-2024) & (M Units)
Table 14. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2019-2024)
Table 15. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2019-2024)
Table 16. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2019-2024)
Table 17. Global Beta-lactam and Beta-lactamase Inhibitors Sale Price by Application (2019-2024) & (US$/Unit)
Table 18. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Company (2019-2024) & (M Units)
Table 19. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Company (2019-2024)
Table 20. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Company (2019-2024) ($ Millions)
Table 21. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Company (2019-2024)
Table 22. Global Beta-lactam and Beta-lactamase Inhibitors Sale Price by Company (2019-2024) & (US$/Unit)
Table 23. Key Manufacturers Beta-lactam and Beta-lactamase Inhibitors Producing Area Distribution and Sales Area
Table 24. Players Beta-lactam and Beta-lactamase Inhibitors Products Offered
Table 25. Beta-lactam and Beta-lactamase Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Geographic Region (2019-2024) & (M Units)
Table 29. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share Geographic Region (2019-2024)
Table 30. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Geographic Region (2019-2024) & ($ millions)
Table 31. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Geographic Region (2019-2024)
Table 32. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Country/Region (2019-2024) & (M Units)
Table 33. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country/Region (2019-2024)
Table 34. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Country/Region (2019-2024) & ($ millions)
Table 35. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country/Region (2019-2024)
Table 36. Americas Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2019-2024) & (M Units)
Table 37. Americas Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2019-2024)
Table 38. Americas Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2019-2024) & ($ Millions)
Table 39. Americas Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2019-2024)
Table 40. Americas Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2019-2024) & (M Units)
Table 41. Americas Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2019-2024) & (M Units)
Table 42. APAC Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2019-2024) & (M Units)
Table 43. APAC Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region (2019-2024)
Table 44. APAC Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2019-2024) & ($ Millions)
Table 45. APAC Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Region (2019-2024)
Table 46. APAC Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2019-2024) & (M Units)
Table 47. APAC Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2019-2024) & (M Units)
Table 48. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2019-2024) & (M Units)
Table 49. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2019-2024)
Table 50. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2019-2024) & ($ Millions)
Table 51. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2019-2024)
Table 52. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2019-2024) & (M Units)
Table 53. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2019-2024) & (M Units)
Table 54. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2019-2024) & (M Units)
Table 55. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2019-2024)
Table 56. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2019-2024) & ($ Millions)
Table 57. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2019-2024)
Table 58. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2019-2024) & (M Units)
Table 59. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2019-2024) & (M Units)
Table 60. Key Market Drivers & Growth Opportunities of Beta-lactam and Beta-lactamase Inhibitors
Table 61. Key Market Challenges & Risks of Beta-lactam and Beta-lactamase Inhibitors
Table 62. Key Industry Trends of Beta-lactam and Beta-lactamase Inhibitors
Table 63. Beta-lactam and Beta-lactamase Inhibitors Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Beta-lactam and Beta-lactamase Inhibitors Distributors List
Table 66. Beta-lactam and Beta-lactamase Inhibitors Customer List
Table 67. Global Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Region (2025-2030) & (M Units)
Table 68. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Region (2025-2030) & ($ millions)
Table 69. Americas Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2025-2030) & (M Units)
Table 70. Americas Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Country (2025-2030) & ($ millions)
Table 71. APAC Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Region (2025-2030) & (M Units)
Table 72. APAC Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Region (2025-2030) & ($ millions)
Table 73. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2025-2030) & (M Units)
Table 74. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Country (2025-2030) & (M Units)
Table 76. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Country (2025-2030) & ($ millions)
Table 77. Global Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Type (2025-2030) & (M Units)
Table 78. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 79. Global Beta-lactam and Beta-lactamase Inhibitors Sales Forecast by Application (2025-2030) & (M Units)
Table 80. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 81. Pfizer Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 82. Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 83. Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 84. Pfizer Main Business
Table 85. Pfizer Latest Developments
Table 86. Novartis (Sandoz) Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 87. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 88. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. Novartis (Sandoz) Main Business
Table 90. Novartis (Sandoz) Latest Developments
Table 91. TEVA Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 92. TEVA Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 93. TEVA Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. TEVA Main Business
Table 95. TEVA Latest Developments
Table 96. Merck & Co. Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 97. Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 98. Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 99. Merck & Co. Main Business
Table 100. Merck & Co. Latest Developments
Table 101. AbbVie (Allergan) Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 102. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 103. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 104. AbbVie (Allergan) Main Business
Table 105. AbbVie (Allergan) Latest Developments
Table 106. Sumitomo Dainippon Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 107. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 108. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 109. Sumitomo Dainippon Main Business
Table 110. Sumitomo Dainippon Latest Developments
Table 111. Hikma Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 112. Hikma Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 113. Hikma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 114. Hikma Main Business
Table 115. Hikma Latest Developments
Table 116. Aurobindo Pharma Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 117. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 118. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 119. Aurobindo Pharma Main Business
Table 120. Aurobindo Pharma Latest Developments
Table 121. Wockhardt Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 122. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 123. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 124. Wockhardt Main Business
Table 125. Wockhardt Latest Developments
Table 126. Lupin Limited Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 127. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 128. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 129. Lupin Limited Main Business
Table 130. Lupin Limited Latest Developments
Table 131. Fresenius Kabi Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 132. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 133. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 134. Fresenius Kabi Main Business
Table 135. Fresenius Kabi Latest Developments
Table 136. B. Braun Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 137. B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 138. B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 139. B. Braun Main Business
Table 140. B. Braun Latest Developments
Table 141. USantibiotics Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 142. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 143. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 144. USantibiotics Main Business
Table 145. USantibiotics Latest Developments
Table 146. Qilu Pharmaceutical Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 147. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 148. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 149. Qilu Pharmaceutical Main Business
Table 150. Qilu Pharmaceutical Latest Developments
Table 151. ACS Dobfar Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 152. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 153. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 154. ACS Dobfar Main Business
Table 155. ACS Dobfar Latest Developments
Table 156. Nichi-Iko (Sagent) Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 157. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 158. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 159. Nichi-Iko (Sagent) Main Business
Table 160. Nichi-Iko (Sagent) Latest Developments
Table 161. Antibiotice Basic Information, Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 162. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Portfolios and Specifications
Table 163. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 164. Antibiotice Main Business
Table 165. Antibiotice Latest Developments

Related Tags

Related Reports

payment cards

Allows one individual to access the purchased report Read More

Allows all employees of an organization to access the purchased report. Internal sharing only Read More

Allows all employees of an organization to access the purchased report. It also permits the use of up to 4 paragraphs or 1 page of the report externally in whitepapers, press releases, and marketing collateral Read More

Buy Now

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Rishika Gupta

Rishika Gupta

Team Lead- Business Development

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (27 July, 2024)
  • Notify To Team (27 July, 2024)
  • Report updation (28 July, 2024)
  • Report Quality Check (28 July, 2024)
  • Report Dispatch (29 July, 2024)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Global Beta-lactam and Beta-lactamase Inhibitors Market Growth 2024-2030

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.